In DLBCL and MCL the mechanisms of resistance are not as well-known as in CLL, where the cause of resistance has been identified to be related in part to mutations at the covalent site (C481) on BTK and also PLCγ2, resulting in a downstream signal activation [74]. The gene discussed is PLCG2; the disease is mantle cell lymphoma.